INZIRQO

Growth

hydrochlorothiazide

NDAORALFOR SUSPENSION
Approved
Jan 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary…

Pharmacologic Class:

Thiazide Diuretic

Clinical Trials (5)

NCT06205407Phase 1Completed

A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma

Started Dec 2023
42 enrolled
Healthy Participants
NCT03205137N/AWithdrawn

Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice

Started Jun 2022
0
Hypertension
NCT03640221Phase 4Withdrawn

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

Started Sep 2018
0
HypertensionDiabetes Mellitus, Type 2
NCT03387657Phase 1Completed

A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide

Started Jan 2018
16 enrolled
Type 2 Diabetes Mellitus
NCT03031496Phase 1Completed

Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Tablets and Reference Product in Healthy Adult Participants Under Fasting Conditions

Started Mar 2017
42 enrolled
Hypertension

Loss of Exclusivity

LOE Date
Jan 23, 2044
217 months away
Patent Expiry
Jan 23, 2044

Patent Records (1)

Patent #ExpiryTypeUse Code
11878022
Jan 23, 2044
Product
U-4139